Indo Borax launches ₹1,505 crore open offer for Kronox at ₹157.27
- Indo Borax launches mandatory open offer for 25.79% of Kronox Lab Sciences
- Offer price set at ₹157.27 per share, totaling ₹1,505 crore if fully accepted
- Acquirers purchased 64.26% stake from promoters for ₹246.12 crore via SPA
- Effective SPA price including consultancy fees is ₹105.87 per share
- IIFL Capital Services appointed as manager to the open offer
*this image is generated using AI for illustrative purposes only.
Kronox Lab Sciences promoters have signed a share purchase agreement (SPA) to sell a controlling stake in the listed chemical firm to Indo Borax & Chemicals Limited and Zenrock Chemicals Private Limited. The deal involves the transfer of 2,38,44,000 equity shares, representing approximately 64.26% of the company’s total paid-up equity capital, for an aggregate consideration of ₹246.12 crore. Indo Borax has now launched a mandatory open offer to public shareholders to acquire an additional 25.79% stake.
The agreement was executed on August 20, 2026, by Mr. Ketan Vinodchandra Ramani, Mr. Pritesh Vinodchandra Ramani, and Mr. Jogindersingh Gianchand Jaswal. Collectively known as the sellers, these promoters currently hold a combined 74.21% stake in the company. The acquirer, Indo Borax & Chemicals Limited, along with Zenrock Chemicals Private Limited acting as persons acting in concert, will assume control upon completion. The indicative time to complete the acquisition is three months from the date of signing the SPA.
Transaction Structure
The base price for the shares under the SPA is ₹103.22 per equity share. However, when inclusive of consultancy fees payable by the company to the sellers for transition support, the effective price rises to ₹105.87 per share. This valuation is calculated in accordance with Regulation 8(7) of the SEBI Substantial Acquisition of Shares and Takeovers (SAST) Regulations.
Key terms of the agreement include:
- The sellers will retain a remaining holding of 9.95%, which is subject to a lock-in period specified in the SPA.
- Upon expiry of the lock-in, any further transfer by the sellers requires the acquirer’s right of first refusal.
- The sellers have undertaken non-compete and non-solicit obligations for an identified period.
- Post-completion, the sellers will enter into a consultancy agreement with the company for a period of 36 months. The aggregate consultancy fee is ₹6.3 crore.
| Parameter | Detail |
|---|---|
| Stake Sold | 64.26% (2,38,44,000 shares) |
| Aggregate Consideration | ₹246.12 crore |
| Base Share Price | ₹103.22 |
| Effective Price (incl. consultancy) | ₹105.87 |
| Acquirer | Indo Borax & Chemicals Limited |
| Date of Execution | August 20, 2026 |
Open Offer Details
Pursuant to Regulation 3(1) and Regulation 4 of the SAST Regulations, 2011, Indo Borax and Zenrock Chemicals have made a mandatory open offer to public shareholders. The offer is for up to 95,70,000 equity shares, representing 25.79% of the voting share capital.
The offer price is fixed at ₹157.27 per equity share. Assuming full acceptance, the total consideration payable under the open offer will be ₹1,505 crore. The offer price is determined in accordance with Regulations 8(1) and 8(2) read with Regulation 8(7) of the SEBI (SAST) Regulations. The payment will be made in cash.
| Offer Parameter | Detail |
|---|---|
| Offer Size | 25.79% (95,70,000 shares) |
| Offer Price | ₹157.27 per share |
| Total Consideration (max) | ₹1,505 crore |
| Manager to Offer | IIFL Capital Services Limited |
| Payment Mode | Cash |
The public announcement was issued on August 20, 2026. The Detailed Public Statement is expected to be published on or before August 28, 2026. The acquirer does not intend to delist the target company. If the public shareholding falls below the minimum requirement after the offer, the acquirer will take steps to ensure compliance with listing norms.
Change in Control
The transaction results in a significant shift in management and control. Upon completion, Indo Borax & Chemicals Limited will be classified as the promoter, while Zenrock Chemicals Private Limited will be part of the promoter group. The existing promoters will cease to be in control and will be reclassified into the public category under Regulation 31A(10) of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations.
Indo Borax & Chemicals Limited will appoint three nominee directors to the board, and the outgoing promoters will resign from their positions. Between the execution date and completion, the sellers have agreed to operate the business in the ordinary course, refraining from material changes such as entering into new related-party contracts, creating asset encumbrances, or declaring dividends without prior written approval from the acquirer.
Strategic Rationale
Suresh Kalra, Managing Director and CEO of Indo Borax Chemicals Ltd., stated that the acquisition is a strategic move towards expansion, diversification, premiumisation, and margin improvement. He noted that Kronox's rich experience and export presence will strengthen Indo Borax's offerings and help fortify margins through synergies.
Ketan Ramani, Promoter and Director of Kronox Lab Sciences Ltd., described the event as the inception of a new innings for the company. He indicated that joining hands with Indo Borax would enable Kronox to accelerate its growth plans, expand its product profile, and explore new avenues.
What the Numbers Show
The open offer price of ₹157.27 represents a significant premium over the SPA effective price of ₹105.87. This pricing structure reflects the mandatory nature of the tender offer under SEBI regulations, which typically require the offer price to be higher than the price paid by the acquirer in the underlying transaction to protect minority shareholders. The substantial difference between the SPA price and the open offer price highlights the regulatory framework's intent to provide exit opportunities to public shareholders at favorable valuations during change-of-control transactions.
Historical Stock Returns for Kronox Lab Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.30% | -4.06% | +4.90% | +53.79% | +4.35% | 0.0% |
How will the integration of Kronox Lab Sciences' export network impact Indo Borax's revenue mix and geographic diversification in the next fiscal year?
What specific operational synergies or cost-saving measures does Indo Borax anticipate achieving to justify the significant premium paid in the open offer?
Will the three-year consultancy agreement with outgoing promoters create potential conflicts of interest or governance challenges during the transition period?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
